当前位置: 首页 >> 检索结果
821. Long-Term Outcomes After Fontan Conversion Operation: A Comparative Analysis Based on Type of Fontan Connection.
作者: Amr Moustafa.;Zeyad Kholeif.;William R Miranda.;Heidi M Connolly.;Elizabeth H Stephens.;Joseph A Dearani.;Alexander C Egbe.
来源: Circ Heart Fail. 2025年18卷12期e012990页
Fontan conversion (FC) is associated with a lower risk of atrial arrhythmias and thromboembolism, but it is unknown whether FC improves long-term survival. The purpose of this study was to assess the impact of FC on transplant-free survival.
822. Outcomes of Ventricular Tachycardia Catheter Ablation in Pediatric Arrhythmogenic Right Ventricular Cardiomyopathy.
作者: Salah H Alahwany.;Shunsuke Uetake.;Juan Jiménez-Jáimez.;Eva Cabrera-Borrego.;Aarti Dalal.;Prince J Kannankeril.;M Benjamin Shoemaker.;Daisuke Togashi.;Yumi Katsume.;Travis D Richardson.;Arvindh Kanagasundram.;William G Stevenson.;Harikrishna Tandri.
来源: Circ Arrhythm Electrophysiol. 2025年18卷11期e014075页
Radiofrequency catheter ablation (RFCA) of ventricular tachycardia (VT) in arrhythmogenic right ventricular cardiomyopathy is safe and reduces ventricular arrhythmia burden. Previous studies included adult patients, and data on pediatric patients are scarce. The objective of our study was to report on the safety and efficacy of RFCA in pediatric arrhythmogenic right ventricular cardiomyopathy.
823. Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.
作者: Fengwen Zhang.;Jie Dong.;Peijian Wei.;Weiyi Fang.;Hao Hu.;Xiangqing Kong.;Ming Bai.;Jiahua Pan.;Zhiling Luo.;Ping Zhang.;Baiming Qu.;Jinpeng Hu.;Yaoxing Lu.;Chuangshi Wang.;Shouzheng Wang.;Xiangbin Pan.
来源: Circulation. 2026年153卷2期71-81页
Novel biodegradable patent foramen ovale (PFO) closure devices offer a promising therapeutic option. The efficacy and safety of the novel biodegradable devices compared with nitinol devices have not yet been investigated in a randomized clinical trial.
824. Relations of AI-Vascular Age Estimated From a Peripheral Pressure Waveform With Incident Atrial Fibrillation: The Framingham Heart Study.
作者: Timothy J Korzinski.;Celestin Hategeka.;Brenton R Prescott.;David J Hamel-Sellman.;Vanessa Xanthakis.;Leroy L Cooper.;Naomi M Hamburg.;Connie W Tsao.;Honghuang Lin.;Ramachandran S Vasan.;Gary F Mitchell.;Emelia J Benjamin.
来源: Circ Arrhythm Electrophysiol. 2025年18卷11期e014383页 825. High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial.
作者: Vivek Y Reddy.;Jacob S Koruth.;Petr Peichl.;Jan Petru.;Moritoshi Funasako.;Jan Skoda.;Keita Watanabe.;Moritz Nies.;Josef Kautzner.;Petr Neuzil.
来源: Circulation. 2025年152卷24期1691-1704页
Unlike the tremendous progress made in atrial fibrillation ablation, the greatest unmet clinical need is for innovative ablation treatments for scar-related ventricular tachycardia (VT), particularly given the thick, often fibrotic tissue characteristic of the scarred substrate. A focal pulsed field ablation (PFA) catheter with a novel waveform was designed: high voltage to provide tissue penetration and low energy (using short-duration pulses) to avoid tissue overheating. We present the outcomes of VCAS (Ventricular Catheter Ablation Study), a first-in-human study of this PFA catheter to ablate scar-related VT.
826. Diastolic Blood Pressure and Cognitive Function in Adults With Achieved Systolic Blood Pressure Below 130 mm Hg: Insights From the SPRINT-MIND Trial.
作者: Ruixue Yang.;Zhou Fang.;Daman Yang.;Lei Zhang.;Qiaoxi Yang.;Qianhui Ling.;Xilan Dong.;Miaomiao Zhuang.;Tianchen Guo.;Sifei Chen.;Yufei Ji.;Jun Cai.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷11期e011902页
The potential J-shaped relationship whereby lower diastolic blood pressure (DBP) is associated with a higher risk of adverse cognitive outcomes has raised concerns regarding intensive systolic blood pressure (SBP) lowering. However, the current guidelines advocate a stricter SBP target of <130 mm Hg, with no clear consensus on a DBP target, especially with respect to brain health. The present study aimed to determine the relationship between treated DBP and cognitive function, as well as cerebral perfusion and structure, in adults who achieved an SBP <130 mm Hg.
828. Multicenter Pivotal Trial of the Minima Stent for Vascular Stenosis in Infants and Young Children.
作者: Patrick M Sullivan.;Evan M Zahn.;Shyam Sathanandam.;Brian Morray.;Shabana Shahanavaz.;Arash Salavitabar.;Aimee K Armstrong.;Diego Porras.;Darren P Berman.
来源: Circ Cardiovasc Interv. 2025年18卷12期e015618页
The Minima Stent System is the first stent designed, tested, and Food and Drug Administration-approved for use in neonates, infants, and children. Our objective was to evaluate the safety and efficacy of Minima implantation for pulmonary artery stenosis (PAS) and coarctation of the aorta (CoA).
829. Trends in Guideline-Directed Medical Therapies and Clinical Management in Patients With Prevalent Versus Incident Heart Failure: A Danish Nationwide Study From 1996 to 2022.
作者: Emma Kidholm Boysen.;Lars Køber.;Mads Kristian Ersbøll.;Trine Kiilerich Lauridsen.;Jesper Jensen.;Emil Wolsk.;Jens Jakob Thune.;Mette Rauhe Mouridsen.;Christian Ditlev Tuxen.;Peter Godsk Jørgensen.;Morten Lamberts.;Emil Fosbøl.;Nadia Dridi.;Morten Petersen.;Nis Ottesen Stride.;Anders Barasa.;Caroline Garred.;Simon Larsen.;Morten Schou.;Mariam Elmegaard.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷12期e012117页 830. Letter by Xu et al Regarding Article "Predictors of Neurodevelopmental and Mental Health Diagnoses in Congenital Heart Disease: A Danish Population-Based Cohort Study".832. Letter by Fauchier et al Regarding Article, "Incidence, Prevalence and Trends in Mortality and Stroke Among Medicare Beneficiaries With Atrial Fibrillation: 2013 to 2019".
作者: Laurent Fauchier.;Lisa Lochon.;Arnaud Bisson.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷12期e012601页 833. Response by Gal et al to Letter Regarding Article, "Predictors of Neurodevelopmental and Mental Health Diagnoses in Congenital Heart Disease: A Danish Population-Based Cohort Study".
作者: Dana B Gal.;Dóra Körmendiné Farkas.;Kristina Laugesen.;Henrik Toft Sørensen.;Nadine A Kasparian.;Nicolas L Madsen.;Kimberley G Miles.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷11期e012690页 834. Cardiovascular Risk Factor Management in Medicare Advantage and Traditional Medicare.
作者: Andrew S Oseran.;Rahul Aggarwal.;Rishi K Wadhera.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷11期e012143页
Although cardiovascular disease is the leading cause of death in the United States among Medicare beneficiaries, management of modifiable risk factors remains suboptimal. Medicare Advantage (MA) enrollment has increased substantially; therefore, understanding the quality of cardiovascular risk factor management in MA is critical. In this study, we evaluated whether cardiovascular risk factor management was better among MA compared with traditional Medicare (TM) beneficiaries.
835. Response by Rogovoy et al to Letter Regarding Article, "Incidence, Prevalence, and Trends in Mortality and Stroke Among Medicare Beneficiaries With Atrial Fibrillation: 2013 to 2019".
作者: Nichole M Rogovoy.;Stephen Kearing.;Weiping Zhou.;James V Freeman.;Jonathan P Piccini.;Sana M Al-Khatib.;Emily P Zeitler.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷12期e012691页 836. Sex Differences in the Relationship Between Psychosocial Stress and Myocardial Tissue Characteristics: A CMR Imaging Study.
作者: Mayssa Moukarzel.;Kian Soroush.;Yixing Zhang.;Jean-Philippe Gouin.;Matthias G Friedrich.;Judy M Luu.
来源: Circ Cardiovasc Imaging. 2025年18卷11期e017667页
Psychosocial stress is linked to the development of cardiovascular disease, with a more pronounced impact in female participants. This study investigates sex differences in the association between perceived stress and myocardial tissue characteristics, as assessed by cardiovascular magnetic resonance imaging, and evaluates the contribution of psychosocial burden, including caregiving and perceived social standing.
837. Utility of 18F-Flurpiridaz PET Relative Flow Reserve in Differentiating Obstructive From Nonobstructive Coronary Artery Disease.
作者: Diana M Lopez.;Daniel M Huck.;Sanjay Divakaran.;Jenifer M Brown.;Brittany N Weber.;Mark Lemley.;Valerie Builoff.;Aakash Shanbhag.;Zhou Lan.;Christopher Buckley.;Mouaz H Al-Mallah.;Sharmila Dorbala.;Ron Blankstein.;Piotr Slomka.;Marcelo F Di Carli.
来源: Circ Cardiovasc Imaging. 2025年18卷11期e018323页
Absolute quantification of myocardial blood flow (MBF) on positron emission tomography perfusion imaging improves the identification of coronary artery disease (CAD). However, distinguishing MBF impairment due to obstructive CAD from nonobstructive CAD remains challenging. We aimed to evaluate the incremental diagnostic value of positron emission tomography derived relative flow reserve (RFR) in the diagnosis of obstructive CAD.
838. Effect of Semaglutide on Atrial Arrhythmias Recurrence Following Ablation for Atrial Fibrillation: A Prospective Study.
作者: Jiongchao Guo.;Ziliang Song.;Shiyi Wang.;Die Yao.;Yu Hong.;Minmin Fu.;Min Chen.;Weifeng Jiang.;Yu Zhang.;Shaohui Wu.;Xu Liu.;Xumin Hou.;Mu Qin.
来源: Circ Arrhythm Electrophysiol. 2025年18卷11期e014069页
Recurrence of atrial arrhythmias remains a significant challenge following catheter ablation for atrial fibrillation. The potential role of semaglutide in reducing atrial arrhythmia recurrence postablation is unclear.
840. Cardiac Ventricular Hinge Point LGE Is Highly Prevalent and Sex-Dependent in ELITE Athletes.
作者: Sjoerd M Verwijs.;Juliette C Van Hattum.;Joëlle J N Daems.;S Matthijs Boekholdt.;R Nils Planken.;Maarten Groenink.;Adrienne van Randen.;Raschel D van Luijk.;Jules L Nelissen.;Maarten H Moen.;Birgitta K Velthuis.;Yigal M Pinto.;Arthur A M Wilde.;Niek H J Prakken.;Harald T Jørstad.; .
来源: Circ Cardiovasc Imaging. 2025年18卷12期e017765页
Myocardial late gadolinium enhancement (LGE) using cardiac magnetic resonance imaging has been described in older endurance athletes, particularly at the ventricular hinge point. However, data on young, elite athletes are lacking. We therefore quantified the prevalence of hinge point LGE (HP-LGE) in young elite-level athletes.
|